[ad_1]
On March 21, 2023 at 11:01:11 ET an unusually large
$265.00K block of Put contracts in Boston Scientific
(BSX) was sold,
with a strike price of $50.00 / share, expiring in 87 days (on June 16, 2023).
Fintel tracks all large options trades, and the premium spent on this trade was 2.92 sigmas above the mean, placing it in the 100.00 percentile of all recent large trades made in BSX options.
This trade was first picked up on Fintel’s real time Unusual Option Trades
tool, where unusual option trades are highlighted.
Analyst Price Forecast Suggests 10.70% Upside
As of March 21, 2023,
the average one-year price target for Boston Scientific is $54.06.
The forecasts range from a low of $45.45 to a high of $61.95.
The average price target represents an increase of 10.70% from its latest reported closing price of $48.83.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Boston Scientific
is $13,569MM, an increase of 6.99%.
The projected annual non-GAAP EPS
is $1.96.
What is the Fund Sentiment?
There are 1827 funds or institutions reporting positions in Boston Scientific.
This is an increase
of
87
owner(s) or 5.00% in the last quarter.
Average portfolio weight of all funds dedicated to BSX is 0.46%,
an increase
of 2.88%.
Total shares owned by institutions decreased
in the last three months by 0.72% to 1,484,943K shares.
The put/call ratio of BSX is 1.13, indicating a
bearish
outlook.
What are Large Shareholders Doing?
Massachusetts Financial Services
holds 81,984K shares
representing 5.71% ownership of the company.
In it’s prior filing, the firm reported owning 84,092K shares, representing
a decrease
of 2.57%.
The firm
decreased
its portfolio allocation in BSX by 99.98% over the last quarter.
Wellington Management Group Llp
holds 57,736K shares
representing 4.02% ownership of the company.
In it’s prior filing, the firm reported owning 62,537K shares, representing
a decrease
of 8.31%.
The firm
increased
its portfolio allocation in BSX by 3.84% over the last quarter.
Jpmorgan Chase &
holds 47,426K shares
representing 3.31% ownership of the company.
In it’s prior filing, the firm reported owning 50,640K shares, representing
a decrease
of 6.78%.
The firm
increased
its portfolio allocation in BSX by 2.71% over the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares
holds 43,541K shares
representing 3.03% ownership of the company.
In it’s prior filing, the firm reported owning 42,686K shares, representing
an increase
of 1.96%.
The firm
increased
its portfolio allocation in BSX by 12.54% over the last quarter.
Primecap Management
holds 37,652K shares
representing 2.62% ownership of the company.
In it’s prior filing, the firm reported owning 37,650K shares, representing
an increase
of 0.00%.
The firm
decreased
its portfolio allocation in BSX by 99.89% over the last quarter.
Boston Scientific Background Information
(This description is provided by the company.)
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, The company advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
[ad_2]
Image and article originally from www.nasdaq.com. Read the original article here.